What changed, and where it came from.
We check official sources every day: the Judicial Panel on Multidistrict Litigation, federal courts, the FDA, EPA, and SSA. An editor verifies each change before it appears here or on a campaign page.
- JPMLSix more federal case groups addedAdded information pages for proton-pump inhibitors (MDL 2789), Bair Hugger warming blankets (MDL 2666), Cook IVC filters (MDL 2570), social media and adolescent harm (MDL 3047), Boston Scientific spinal cord stimulators (MDL 3181) and ByHeart infant formula (MDL 3178). Counts are from the JPML report dated Oct 1, 2026.View source (opens in a new tab)
- JPMLOctober pending-case report publishedPending-case counts refreshed on every campaign page with a federal case group. Largest moves since September: Roundup (MDL 2741) fell from 3,925 to 1,104; Elmiron (MDL 2973) from 286 to 186; Bard PowerPort (MDL 3081) rose from 3,734 to 4,140; Uber (MDL 3084) from 4,588 to 4,916.View source (opens in a new tab)
- JPMLMonthly pending-case report publishedPending-case counts refreshed on every campaign page with a federal case group, after editor review.View source (opens in a new tab)
- PfizerOxbryta will not return to the U.S. marketStatus stays at Monitoring. There is no consolidated federal case group at this time.View source (opens in a new tab)
- FDAFDA finishes ByHeart facility inspectionsFDA completed on-site inspections of ByHeart facilities on June 3, 2026. It found the bacterium in a powdered milk ingredient but has not determined the root cause. CDC declared the outbreak over on Feb 26, 2026.View source (opens in a new tab)
- FDAMeningioma added to Depo-Provera warningsFDA approved labeling that adds meningioma to Warnings and Precautions.View source (opens in a new tab)